AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12125943 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 1106
Study 12125943 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol
Number of subjects: 1106
Study 10594518 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous GHRH(1-29)NH2 (60 ng/kg/min, subcutaneous infusion, 24 h)
Number of subjects: 12
Study 10594518 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent SS(1-14) withdrawal (20 microg/m2/hour, intravenous infusion, 3 h on/1 h off, 2-3 cycles over 8-12 h)
Number of subjects: 12
Study 10594518 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining continuous GHRH with intermittent SS
Number of subjects: 12
Study 10594518 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous GHRH
Number of subjects: 12
Study 10594518 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining intermittent SS with continuous GHRH
Number of subjects: 12
Study 10594518 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous GH release in irradiated subjects
Number of subjects: 12
Study 7786264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ansell Gammex gloves
Number of subjects: 0
Study 7786264 — intervention group
Group type: COMPARATOR
Intervention: Baxter Triflex gloves
Number of subjects: 0
Study 2072886 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral supplementation with folic acid before conception and during early pregnancy
Number of subjects: 0
Study 6864702 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine combined with methohexitone
Number of subjects: 0
Study 6864702 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate combined with methohexitone
Number of subjects: 0
Study 6864702 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 0
Study 6864702 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate
Number of subjects: 0
Study 6864702 — intervention group
Group type: COMPARATOR
Intervention: Atropine and Glycopyrrolate
Number of subjects: 0
Study 30950711 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezum® System thermal therapy
Number of subjects: 188
Study 30950711 — intervention group
Group type: COMPARATOR
Intervention: Control (sham rigid cystoscopy)
Number of subjects: 188
Study 30041267 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons' evaluation of nasal appearance
Number of subjects: 100
Study 30041267 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' self-assessment of nasal appearance
Number of subjects: 100
Study 30041267 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmedical raters' evaluation of nasal appearance
Number of subjects: 100
Study 23328549 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib plus best supportive care (BSC)
Number of subjects: 585
Study 23328549 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 585
Study 21886293 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Foods Hawai'i (HFH) intervention
Number of subjects: 0
Study 21886293 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 19474141 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (18 g) + isoflavone tablets (105 mg isoflavone aglycone equivalents)
Number of subjects: 131
Study 19474141 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein + placebo tablets
Number of subjects: 131
Study 19474141 — intervention group
Group type: EXPERIMENTAL
Intervention: Control protein + isoflavone tablets
Number of subjects: 131
Study 19474141 — intervention group
Group type: COMPARATOR
Intervention: Control protein + placebo tablets
Number of subjects: 131
Study 19474141 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dietary protein (per kg)
Number of subjects: 131
Study 17556683 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrandomized SSOB
Number of subjects: 16
Study 17556683 — intervention group
Group type: COMPARATOR
Intervention: Randomized SSOB
Number of subjects: 16
Study 15551252 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin-based regimen (pantoprazole 40 mg, amoxicillin 1 g, levofloxacin 250 mg, all twice daily for 10 days)
Number of subjects: 90
Study 15551252 — intervention group
Group type: COMPARATOR
Intervention: Quadruple therapy (omeprazole 20 mg twice daily for the first week, then omeprazole 20 mg twice daily, tetracycline 250 mg 4 times daily, metronidazole 500 mg twice daily, and bismuth subcitrate 240 mg twice daily for the second week)
Number of subjects: 90
Study 11721144 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 729
Study 11721144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 729
Study 9164809 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 994
Study 9164809 — intervention group
Group type: COMPARATOR
Intervention: Conventional anterior surgery
Number of subjects: 994
Study 7711420 — intervention group
Group type: EXPERIMENTAL
Intervention: MFP‐Ca (13.2 mg fluoride) twice a day
Number of subjects: 20
Study 7711420 — intervention group
Group type: COMPARATOR
Intervention: NaF (11.3 mg fluoride) twice a day
Number of subjects: 20
Study 3117898 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIgG pH 4.25
Number of subjects: 39
Study 3117898 — intervention group
Group type: COMPARATOR
Intervention: IVIgG pH 6.8
Number of subjects: 39
Study 29850873 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 65
Study 27132405 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 0
Study 27132405 — intervention group
Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 0
Study 24492839 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation (1000 mg of vitamin C and 235 mg of vitamin E daily for 11 weeks)
Number of subjects: 54
Study 24492839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 24492839 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation
Number of subjects: 54
Study 22532959 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% glutaraldehyde
Number of subjects: 40
Study 22532959 — intervention group
Group type: EXPERIMENTAL
Intervention: 15.5% ferric sulfate
Number of subjects: 40
Study 22532959 — intervention group
Group type: EXPERIMENTAL
Intervention: formocresol
Number of subjects: 40
Study 22532959 — intervention group
Group type: COMPARATOR
Intervention: control group (distilled water for 48 hours)
Number of subjects: 40
Study 20533969 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) for 6 months
Number of subjects: 45
Study 20533969 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (SPIRO) for 6 months
Number of subjects: 45
Study 19839515 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedures in the facial area (group I)
Number of subjects: 131
Study 19839515 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious prognosis (group II)
Number of subjects: 131
Study 19839515 — intervention group
Group type: COMPARATOR
Intervention: Healthy patients (group III)
Number of subjects: 131
Study 15805990 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 164
Study 15805990 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 164
Study 15805990 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS therapy based on changes in sputum eosinophil counts
Number of subjects: 164
Study 15805990 — intervention group
Group type: COMPARATOR
Intervention: ICS
Number of subjects: 164
Study 15805990 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum eosinophil counts
Number of subjects: 164
Study 12853535 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% LCTs/50% MCTs 20% lipid emulsion
Number of subjects: 18
Study 12853535 — intervention group
Group type: COMPARATOR
Intervention: 20% fat emulsion containing 100% long-chain triglycerides (LCTs)
Number of subjects: 18
Study 10655924 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% pentastarch in 0.9% saline
Number of subjects: 160
Study 10655924 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's solution
Number of subjects: 160
Study 8866058 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal Teaching
Number of subjects: 46
Study 8866058 — intervention group
Group type: EXPERIMENTAL
Intervention: Text Analysis Training
Number of subjects: 46
Study 8866058 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 46
Study 1499250 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine rinse, 15 ml solution, twice daily for 30 seconds
Number of subjects: 36
Study 1499250 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 36
Study 6092011 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose prophylaxis with cefotaxime
Number of subjects: 60
Study 6092011 — intervention group
Group type: COMPARATOR
Intervention: Multiple dose prophylaxis with cefotaxime for 24 hours
Number of subjects: 60
Study 31707262 — intervention group
Group type: COMPARATOR
Intervention: WHO growth standards (W-group)
Number of subjects: 15019
Study 31707262 — intervention group
Group type: EXPERIMENTAL
Intervention: Shanghai growth standards (S-group)
Number of subjects: 15019
Study 29624800 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix (240 mg initial dose, 480 mg maintenance every 84 days)
Number of subjects: 234
Study 29624800 — intervention group
Group type: COMPARATOR
Intervention: Goserelin (3.6 mg initial dose, 10.8 mg maintenance every 84 days)
Number of subjects: 234
Study 29624800 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 234
Study 27660650 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Yunu-Jian (mYJ)
Number of subjects: 25
Study 27660650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 27660650 — intervention group
Group type: EXPERIMENTAL
Intervention: mYJ
Number of subjects: 25
Study 23851424 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine infusion
Number of subjects: 31
Study 21932141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dragon boat paddling
Number of subjects: 120
Study 21932141 — intervention group
Group type: COMPARATOR
Intervention: Group-based walking
Number of subjects: 120
Study 20698799 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporine 0.05%
Number of subjects: 233
Study 20698799 — intervention group
Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 233
Study 17537770 — intervention group
Group type: EXPERIMENTAL
Intervention: AHR strategy (n = 102)
Number of subjects: 210
Study 17537770 — intervention group
Group type: COMPARATOR
Intervention: Reference strategy (n = 104)
Number of subjects: 210
Study 15793394 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP laser treatment during staged intact canal wall surgery
Number of subjects: 69
Study 15793394 — intervention group
Group type: COMPARATOR
Intervention: No KTP laser treatment during staged intact canal wall surgery
Number of subjects: 69
Study 11952445 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectally administered diclofenac (Voltaren) 1 mg/kg
Number of subjects: 50
Study 11952445 — intervention group
Group type: COMPARATOR
Intervention: i.v. opioid (morphine) 0.05 mg/kg
Number of subjects: 50
Study 9443925 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of alendronate daily
Number of subjects: 1174
Study 9443925 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of alendronate daily
Number of subjects: 1174
Study 9443925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1174
Study 9443925 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-progestin
Number of subjects: 1174
Study 7639416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast (10 mg)
Number of subjects: 41
Study 7639416 — intervention group
Group type: COMPARATOR
Intervention: Elastase (1800 U)
Number of subjects: 41
Study 2236462 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment for children with pure depression or depression plus an anxiety-related disorder
Number of subjects: 31
Study 2236462 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for children with pure depression or depression plus an anxiety-related disorder
Number of subjects: 31
Study 2236462 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment for children with depression plus a concomitant conduct or oppositional disorder
Number of subjects: 31
Study 2236462 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for children with depression plus a concomitant conduct or oppositional disorder
Number of subjects: 31
Study 890229 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse axial emission tomography (tomographic section view)
Number of subjects: 29
Study 890229 — intervention group
Group type: COMPARATOR
Intervention: Conventional views (without tomographic section view)
Number of subjects: 29
Study 31821071 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose tamoxifen (ID arm; 40 mg daily)
Number of subjects: 186
Study 31821071 — intervention group
Group type: COMPARATOR
Intervention: Regular dose tamoxifen (RD arm; 20 mg daily)
Number of subjects: 186
Study 31821071 — intervention group
Group type: COMPARATOR
Intervention: Homozygous wild-type (wt/wt) patients (20 mg daily)
Number of subjects: 186
Study 30244144 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold nanosecond laser (SNL) treatment
Number of subjects: 292
Study 30244144 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 292
Study 26443829 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypertension
Number of subjects: 25
Study 26443829 — intervention group
Group type: COMPARATOR
Intervention: Control (no induced hypertension)
Number of subjects: 25
Study 23695747 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder symptoms among polio survivors
Number of subjects: 272
Study 23695747 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in bladder symptoms
Number of subjects: 272
Study 23695747 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence prevalence
Number of subjects: 272
Study 23695747 — intervention group
Group type: COMPARATOR
Intervention: Comparison with background population
Number of subjects: 272
Study 21558066 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (5 g daily) administered intraoperatively and on days 1 and 2 after operation
Number of subjects: 200
Study 21558066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 21558066 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (5 g daily) in patients undergoing pneumonectomy
Number of subjects: 200
Study 21558066 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients undergoing pneumonectomy
Number of subjects: 200
Study 18823363 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment from the start without detoxification
Number of subjects: 56
Study 18823363 — intervention group
Group type: COMPARATOR
Intervention: Standard out-patient detoxification programme without prophylactic treatment from the start
Number of subjects: 56
Study 18823363 — intervention group
Group type: COMPARATOR
Intervention: No specific treatment (5-month follow-up)
Number of subjects: 56
Study 17003291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 296
Study 17003291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 12637400 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 4926
Study 12637400 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid-iron
Number of subjects: 4926
Study 12637400 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid-iron-zinc
Number of subjects: 4926
Study 12637400 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients
Number of subjects: 4926
Study 12637400 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A alone
Number of subjects: 4926
Study 11056756 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 33
Study 11056756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 9176898 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated glaucomatous eyes
Number of subjects: 15
Study 9176898 — intervention group
Group type: COMPARATOR
Intervention: Normal control eyes
Number of subjects: 15
Study 8252502 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate plus flutamide
Number of subjects: 264
Study 8252502 — intervention group
Group type: COMPARATOR
Intervention: Bilateral orchiectomy
Number of subjects: 264
Study 2936956 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Angioplasty
Number of subjects: 56
Study 2936956 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary Streptokinase
Number of subjects: 56
Study 30249470 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega 3
Number of subjects: 113
Study 30249470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 30088452 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of chemotherapy plus knockdown or mimicking microRNA
Number of subjects: 0
Study 30088452 — intervention group
Group type: EXPERIMENTAL
Intervention: Antagonist oligonucleotides like antagomiRs or anti-miRs and microRNA mimicking
Number of subjects: 0
Study 26686359 — intervention group
Group type: EXPERIMENTAL
Intervention: Onion juice (100 mL daily for 8 weeks)
Number of subjects: 24
Study 26686359 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 24
Study 25262636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion
Number of subjects: 37
Study 25262636 — intervention group
Group type: COMPARATOR
Intervention: Continuous perfusion
Number of subjects: 37
Study 22549092 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab 20 mg
Number of subjects: 149
Study 22549092 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab 40 mg
Number of subjects: 149
Study 22549092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 22549092 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 149
Study 20569714 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal evidence-based medical therapy (use of all 4 indicated medications)
Number of subjects: 9294
Study 20569714 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs
Number of subjects: 9294
Study 20569714 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 9294
Study 20569714 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-Is/ARBs
Number of subjects: 9294
Study 20569714 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 9294
Study 20569714 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal evidence-based medical therapy
Number of subjects: 9294
Study 18390443 — intervention group
Group type: EXPERIMENTAL
Intervention: Quibron SR tablets 300 mg
Number of subjects: 12
Study 18390443 — intervention group
Group type: COMPARATOR
Intervention: Respro-SR pellets filled Capsules 300 mg
Number of subjects: 12
Study 16206579 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive load and early administration of antioxidants (Group 2), enterally fed with Berlamine-modular for 5 days before surgery and in the postoperative period.
Number of subjects: 100
Study 16206579 — intervention group
Group type: EXPERIMENTAL
Intervention: High oxygen supply values at all stages of surgical treatment (Group 3), optimized infusion therapy and compensated intraoperative blood loss.
Number of subjects: 100
Study 16206579 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive approach to preventing ARF (Group 4), prevention of ischemia and reperfusion, optimized blood oxygen-transporting function.
Number of subjects: 100
Study 16206579 — intervention group
Group type: COMPARATOR
Intervention: Control group, no use of aminoglycosides, prevention of hyperglycemia, provision of steady-state hemodynamics.
Number of subjects: 100
Study 12471316 — intervention group
Group type: EXPERIMENTAL
Intervention: OMNI RPE scale
Number of subjects: 57
Study 12471316 — intervention group
Group type: EXPERIMENTAL
Intervention: Borg RPE scale
Number of subjects: 57
Study 10594520 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.15 units/kg, iv) induced hypoglycaemia
Number of subjects: 40
Study 10594520 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (100 mg, iv) with and without pyridostigmine (120 mg orally)
Number of subjects: 40
Study 10594520 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous nocturnal GH secretion
Number of subjects: 40
Study 10594520 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGF‐I
Number of subjects: 40
Study 7600433 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 41
Study 7600433 — intervention group
Group type: COMPARATOR
Intervention: SD-Ag (control group)
Number of subjects: 41
Study 2328558 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic agent
Number of subjects: 0
Study 2328558 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic plus antihistaminic agent
Number of subjects: 0
Study 2328558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 535832 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate therapy
Number of subjects: 0
Study 30439452 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo analgesia (PA) condition
Number of subjects: 0
Study 30439452 — intervention group
Group type: COMPARATOR
Intervention: Cold-pain condition
Number of subjects: 0
Study 28039212 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lead atrial pacing (AAIR)
Number of subjects: 1384
Study 28039212 — intervention group
Group type: COMPARATOR
Intervention: Dual chamber pacing (DDDR)
Number of subjects: 1384
Study 25772806 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load very high-repetition resistance training (BodyPump™)
Number of subjects: 50
Study 25772806 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 23527358 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehydrated corticocancellous porcine bone (PCPB)
Number of subjects: 37
Study 23527358 — intervention group
Group type: COMPARATOR
Intervention: 100% deproteinated particulated bovine bone (DPBB)
Number of subjects: 37